Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation

Kazuaki Miyagawa, …, G. David Roodman, Noriyoshi Kurihara

JCI Insight. 2023;8(14):e159838. https://doi.org/10.1172/jci.insight.159838.

Graphical abstract

Find the latest version:
https://jci.me/159838/pdf
Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation

Kazuaki Miyagawa,1 Hirofumi Tenshin,1 Patrick L. Mulcrone,1 Jesus Delgado-Calle,2 Mark A. Subler,3 Jolene J. Windle,1 John M. Chirgwin,1,4 G. David Roodman,1 and Noriyoshi Kurihara1

1Division of Hematology and Oncology, Department of Medicine, Indiana University, Indianapolis, Indiana, USA. 2Department of Physiology & Cell Biology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 3Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA. 4Research Service, Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.

Introduction

Paget disease (PD) of bone usually occurs in patients over 50 years of age and represents the most exaggerated example of coupled bone remodeling (1). Patients with PD have characteristic pagetic lesions (PDLs) that are highly localized areas in bone, where both osteoclast (OCL) and osteoblast (OB) activities are markedly increased. This results in local overproduction of poor-quality bone that can cause significant clinical problems (1). Interestingly, patients with PD rarely develop new focal lesions over the course of their disease. The primary cellular abnormality in PD resides in the osteoclast (2), because highly effective PD treatments that target OCL activity, such as zoledronic acid, also normalize the rapid bone formation (3).

We previously reported that measles virus nucleocapsid protein (MVNP) expression in osteoclasts (OCLs) of patients with Paget disease (PD) or targeted to the OCL lineage in MVNP-transgenic mice (MVNP mice) increases IGF1 production in osteoclasts (OCL-IGF1) and leads to development of PD OCLs and pagetic bone lesions (PDLs). Conditional deletion of Igf1 in OCLs of MVNP mice fully blocked development of PDLs. In this study, we examined whether osteocytes (OCys), key regulators of normal bone remodeling, contribute to PD. OCys in PDLs of patients and of MVNP mice expressed less sclerostin, and had increased RANKL expression compared with OCys in bones from WT mice or normal patients. To test whether increased OCL-IGF1 is sufficient to induce PDLs and PD phenotypes, we generated TRAP-Igf1 (T-Igf1) transgenic mice to determine whether increased IGF1 expression in the absence of MVNP in OCLs is sufficient to induce PDLs and pagetic OCLs. We found that T-Igf1 mice at 16 months of age developed PD OCLs, PDLs, and OCys, with decreased sclerostin and increased RANKL, similar to MVNP mice. Thus, pagetic phenotypes could be induced by OCLs expressing increased IGF1. OCL-IGF1 in turn increased RANKL production in OCys to induce PD OCLs and PDLs.
(OCys) within the pre-PD niche, provides an attractive mechanism. OCys are the most abundant and long-lived cells in bone, derived from late OB lineage cells that become imbedded within mineralized matrix and intercommunicate via neurite-like extensions between cells within bone canaliculi. OCys are critical regulators of local bone remodeling, the primary source of receptor activator of NF-κB ligand (RANKL) in adult bone, and producers of and responders to IGF1 (10). However, little is known about their contributions to PD. Here we report that OCys are abnormal in PD. We generated mice expressing Igf1 under the control of the tartrate-resistant acid phosphatase (TRAP) promoter (T-Igf1 mice) to test whether high levels of OCL-IGF1 alone are sufficient to induce PDLs. T-Igf1 mice developed PDLs and pagetic OCLs and OCys at 16 months of age. Furthermore, OCys from MVNP and T-Igf1 mice secreted high amounts of RANKL and low sclerostin in response to OCL-IGF1, suggesting a mechanism by which high IGF1 produced by PD OCLs promotes a positive feedback loop between OCLs and OCys, leading to development of PDLs.

Results

OCys in MVNP mice and patients with PD are abnormal. To characterize the effects of increased OCL-derived IGF1 on OCys in PD, we analyzed sclerostin expression in bone sections of femurs from 20-month-old WT, Igf1-cKO, MVNP, and MVNP/Igf1-cKO mice.

OCys in MVNP mice showed lower sclerostin staining compared with the other genotypes (Figure 1A), and the numbers of sclerostin-expressing OCys per bone area were also significantly reduced compared with the other genotypes (Figure 1B). However, circulating serum sclerostin concentrations were similar in all genotypes (Figure 1C). OCys in MVNP mice were morphologically abnormal and had very short dendritic processes compared with the well-developed dendritic processes of OCys in WT, Igf1-cKO, and MVNP/Igf1-cKO mice (Figure 1A, arrow). Canalicular length of OCys in MVNP mice was also significantly shorter than in the other genotypes (Figure 1D, P < 0.001), but did not appear to be sexually dimorphic. Importantly, OCys in a bone biopsy from a patient with PD were similarly abnormal and showed reduced sclerostin expression and shorter dendritic processes compared with OCys in a bone biopsy of a normal patient (Figure 1E, arrow).

OCy morphology and sclerostin expression in PDLs. We and others previously found that OCLs are increased in number and hypermineralized in PDLs (1–3). Therefore, we examined OCys in PDLs that were characterized by such OCLs. As shown in Figure 1, in bone areas in mice without PDLs, sclerostin expression and dendritic processes of OCys in MVNP mice were significantly reduced compared with WT mice. Sclerostin expression and dendritic processes of OCys were further reduced in MVNP mouse sites of PDLs (Figure 2A), which also had lower numbers of sclerostin-expressing OCys per bone area and decreased canalicular length compared with MVNP mice without PDLs or WT mice (Figure 2, B and C). These results suggest that OCys may contribute to the increased pagetic OCL formation and to formation of PDLs.

Characteristics of primary OCys from bones of WT and MVNP mice. Since sclerostin expression and dendrite formation are characteristics of mature OCys (11), and OCys produce IGF1 (12), we analyzed Sost and Igf1 mRNAs in primary OCys isolated by collagenase digestion of long bones from 20-month-old WT and MVNP mice. Sost gene expression in OCys of MVNP mice was reduced by 30% compared with WT mice, while Igf1 gene expression in OCys from WT and MVNP mice was unchanged (Figure 3A). Fluorescent immunostaining of primary OCys from MVNP mice showed decreased average intensity of staining for the OCy maturation markers DMP1 and sclerostin compared with OCys in WT mice (Figure 3, B and C). These results suggest that OCys may contribute to the increased pagetic OCL formation and to formation of PDLs.

Since only a limited numbers of OCys can be obtained by collagenase digestion, we isolated OBs and OCys derived from bone outgrowth cells of WT and MVNP mice. Differentiated OBs can be detected in outgrowth cells in bones from MVNP and WT mice at day 15 of culture, and when cultured for an additional 15 days, they differentiate into OCy-like cells. Outgrowth cells from bone reflect the phenotype of OCys in bone (9) and demonstrate that OCy maturation appears decreased in OCys-like cells from MVNP mice (Supplemental Figure 1, A–C; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.159838DS1). Furthermore, OCy-like cells from bones of MVNP mice produced and secreted less sclerostin than OCy-like cells derived from the other 3 genotypes (Supplemental Figure 1D).

OCys from MVNP mice express increased RANKL compared with WT, Igf1-cKO, and MVNP/Igf1-cKO mice. Since OCy-derived RANKL plays a key role in OCL formation (10–15), we examined RANKL expression by OCys in bone sections of 20-month-old mice. We found that OCys of MVNP mice expressed increased RANKL compared with OCys of WT and MVNP/Igf1-cKO mice (Figure 4A). Interestingly, the numbers of RANKL-expressing OCys per bone area in MVNP mice were higher than in the other genotypes (Figure
RANKL released into conditioned media (CM) of OCys from MVNP mice was also significantly higher than in OCy CM of the other genotypes (P<0.01) (Figure 4D). We then determined whether RANKL mRNA in primary OCys isolated by collagenase digestion was also increased in MVNP mice compared with WT mice and found this to be the case (P<0.01) (Supplemental Figure 2, A and B). Thus, RANKL production by the 30-day outgrowth cells from bone reflected differences in RANKL production by primary OCys in WT and MVNP mouse bones, with increased RANKL production by MVNP OCy–like cells compared with WT OCy–like cells. Furthermore, RANKL was also increased in OCy-like cells from MVNP mice at the protein level (31-kDa band), which is the membrane-bound form of RANKL (Supplemental Figure 2, C–E).

OCL-IGF1 increases RANKL production by OCys and induces formation of PD OCLs. We then asked whether the large amounts of OCL-IGF1 secreted by MVNP mice could increase RANKL production by OCys and contribute to pagetic OCL formation in cocultures of OCL precursors and OCys from either WT or MVNP mice. When MVNP OCL precursors were cocultured with MVNP OCy–like cells, OCL formation and RANKL in culture media were increased 2.5-fold compared with cocultures of WT OCL precursors with WT OCy–like cells, with intermediate levels of OCL formation and RANKL production seen in WT/MVNP mixed cocultures (Figure 5, A, B, and D). As shown by the arrows in Figure 5C, PD-like hyperminucleated OCLs only formed in cocultures of MVNP OCL precursors with MVNP OCy–like cells. IGF1 levels were only increased in media of cocultures containing OCL precursors from MVNP mice, regardless of
whether OCys of WT or MVNP mice were in the coculture (Figure 5E). Thus, increased IGF1 is secreted by OCL precursors and OCLs from MVNP mice rather than by OCys in the cocultures.

Since IGF1 from OCLs could increase OCL formation via autocrine actions on OCLs (9), we examined the contribution of OCL-IGF1 to OCL formation in cultures of purified OCL precursors treated with an anti-IGF1 or anti–IGF1 receptor (anti-IGF1R) antibody in the absence of OCys. Treatment with anti–IGF1 or anti-IGF1R inhibited OCL formation by 25% in WT OCL precursor cultures and 40%–60% in MVNP OCL precursor cultures (Supplemental Figure 3A). We then assessed RANKL produced by OBs and OCys from MVNP and WT mice in CM of OBs and OCy-like cells cultured for 72 hours. Although both OBs and OCy-like cells secreted RANKL, OCy-like cells secreted more RANKL than OB (P < 0.001), and RANKL secretion was significantly higher in CM from MVNP OCys compared with CM of WT OCys (Supplemental Figure 3B). Thus, OCL-IGF1 from MVNP mice increases OCL formation in part via autocrine mechanisms, and via MVNP OCy–like cells, which express higher RANKL, and further increase OCL numbers and PD-like OCL formation (Figure 5, A–C).

Figure 2. Changes in osteocyte morphology and sclerostin expression within pagetic lesions of MVNP mice. (A) OCy phenotype (upper panels, sclerostin immunostaining as in Figure 1A, scale bars: 20 μm) and Alexa Fluor 488–phalloidin fluorescent staining for F-actin of sections adjacent to those above to show osteocyte dendritic processes (lower panels, scale bars: 5 μm) in bone specimens from 20-month-old WT and MVNP mice with and without PD lesions (PDLs). (B) Canalicular length per 0.5 mm² was measured as in Figure 1D. (C) Numbers of sclerostin-positive OCys per 100 randomly counted OCys in 3 biological replicates from WT and MVNP mice, shown as mean ± SEM, analyzed by 1-way ANOVA with Tukey’s test.
OCL formation in cocultures of OCL precursors and OCy-like cells is decreased by transducing OCys with Igf1r siRNA or treatment with anti-IGF1 or anti-IGF1R. We then asked whether OCL-IGF1 was directly increasing RANKL production in OCys. When MVNP OCys transduced with Igf1r siRNA (MVNP-IGF1R siRNA-OCy) or control siRNA were cocultured with MVNP OCL precursors, OCL formation and RANKL in CM of cocultures containing MVNP-IGF1R siRNA-OCys were significantly lower (by 65%) compared with MVNP-control siRNA-OCys cocultures (Figure 6, A and B). The Igf1r siRNA–transduced OCy-like cells from WT and MVNP mice still had suppressed IGF1R expression after 48 hours (Supplemental Figure 4).

Further, addition of anti-IGF1 or anti-IGF1R to OCL/OCy cocultures inhibited OCL formation and decreased RANKL levels in CM of MVNP OCL precursors cocultured with MVNP OCys (by 80%) compared with vehicle or control IgG cocultures (Figure 6, C and D). In addition, development of PD-like OCLs by MVNP OCL precursors was also decreased in these cocultures (data not shown). Similar inhibition of OCL formation was observed in coculture of WT OCL precursors and WT OCy (70%), but RANKL levels in CM were below the detection range of the RANKL ELISA. We also found that OCys in coculture adopted a spindle shape when the action of IGF1 was blocked.

Bone resorption capacity of OCLs cocultured with OCy-like cells. To test the bone resorption capacity of OCLs formed in cocultures of OCL precursors with OCys, the same numbers of OCLs and OCy-like cells were cocultured without RANKL on bone slices for 72 hours. Coculture of MVNP OCLs with MVNP OCy–like cells formed numerous large resorption pits, while coculture of WT OCLs with WT OCy–like cells formed
low numbers of small pits (Figure 7A). Anti-IGF1R treatment of MVNP OCL precursors cocultured with MVNP OCys on bone slices decreased the bone resorption rate by 80% compared with bone resorption in control-IgG-treated cocultures (Figure 7B). In contrast, anti-IGF1R decreased bone resorption rates in cocultures of WT OCLs with WT OCy–like cells by 30%. WT OCy/MVNP OCL and MVNP/WT OCL cocultures were not evaluated in the bone resorption pit analysis, because the number of OCLs formed and the concentration of RANKL in the coculture medium (Figures 5 and 6) were too low to demonstrate bone resorption.

**T-Igf1 mice expressed PDLs like those seen in MVNP mice.** To test whether high levels of OCL-IGF1 alone are sufficient to induce PDLs and pagetic OCLs, we generated a T-Igf1 mouse that overexpresses IGF1 in OCLs. To confirm the role of OCL-IGF1 obtained in MVNP mice, we selected T-Igf1 mice as founders with the same level of OCL-IGF1 as in MVNP mice (mice expressing twice as much IGF1 as in WT mice). T-Igf1 mice were aged to assess whether they develop PDLs and pagetic OCLs at 16 months of age for comparison to similar ages of MVNP and WT mice. OCLs from bone marrow (BM) culture of these T-Igf1 mice express IGF1 at the same level as MVNP mice and express twice as much IGF1 as WT, as shown in Supplemental Figure 7A. Interestingly, the expression of IL-6 in OCLs of T-Igf1 mice was at the same level as in WT mice.
and lower than in MVNP mice. Furthermore, OCL-IGF1 levels in the bones of T-Igf1 and MVNP mice were detected at similar levels and more strongly stained with anti-IGF1 than in WT, as shown in Figure 8A. There was no difference in plasma IGF1 levels between WT and T-Igf1 mice (Supplemental Figure 7B).

T-Igf1 mice developed the same PD phenotype as MVNP mice (Figure 8B). Mice of this age were examined because we most consistently find PDLs in MVNP mice at 12 months of age or older (9). PDLs were detectable in 50% of T-Igf1 mice (6 of 12) by μCT and histological analysis (Table 1) and found in vertebrae, femurs, and tibiae. The number of PDLs formed ranged from 1 to 5 in each bone. The results of μCT analysis (Figure 8C) and histological analysis (Figure 8E) in T-Igf1 mice were similar to MVNP mice. Very large OCLs also appeared in T-Igf1 mice (Figure 8D). These results suggest that IGF1 is the major OCL product driving PDL formation in the MVNP model. Even in the absence of MVNP and IL-6 in OCLs, IGF1 alone facilitates PDL formation.

Furthermore, OCys in T-Igf1 mice showed lower sclerostin staining compared with WT mice (Figure 8F), and the numbers of sclerostin-expressing OCys per bone area were also significantly reduced compared with WT mice (Figure 8G). Canalicular length of OCys in T-Igf1 mice was also shorter in MVNP mice (Figure 8G). DMP1 expression was also lower in OCys of T-Igf1 mice than in WT (data not shown). These results are similar to the observations in MVNP mice shown in Figure 1, A and B.

Detection of p-Akt, RANKL, and p16INK4A in WT, MVNP, and T-Igf1 mice. Since IGF1 stimulates phosphorylation of PI3K/Akt via IGF1R (9), we examined p-Akt expression in bones from these mice. Interestingly, more p-Akt staining was observed in T-Igf1 and MVNP than in WT mice (Figure 9A). OCys and OCLs from MVNP and T-Igf1 mice stained positively for p-Akt compared with OCys and
OCLs from WT mice. These results suggest that OCL-IGF1 not only transduces signals to OBL and OCys via IGF1R, but also has autocrine effects on OCLs, as shown Supplemental Figure 3A.

Next, we assessed IGF1 effects on OCys by histomorphology. We stained for TRAP and RANKL by IHC of bones from T-\textit{Igf1} and WT mice. OCys near OCLs expressed more RANKL in T-\textit{Igf1} mice than in WT mice (Figure 9B). These results are similar to RANKL production in OCys of \textit{MVNP} mice, as shown Figure 4.

Farr et al. recently reported that the removal of senescent OCys reduced RANKL production by OCys and restored osteogenesis (16). Therefore, we examined the production of \textit{p16INK4a} and RANKL in \textit{MVNP}, T-\textit{Igf1}, and WT mice. \textit{p16INK4a} and RANKL were visualized by immunofluorescent staining in single cells. The expression of \textit{p16INK4a} and RANKL in \textit{MVNP} and T-\textit{Igf1} mice was stronger than in WT (Figure 9C). \textit{p16INK4a} and RANKL-positive OCys were counted within 250-\mu m² areas at 500 \mu m below the growth plate. The ratio of \textit{p16INK4a} and RANKL-positive OCys of \textit{MVNP} and T-\textit{Igf1} mice was increased 2.5- to 3.5-fold compared with WT. Moreover, \textit{p16INK4a}/RANKL double-positive OCys accounted for 25% of total OCys in \textit{MVNP} and T-\textit{Igf1} mice, which was 3-fold higher than WT (Figure 9D). The results confirm previous observations that RANKL production is part of senescence-associated secretory phenotype of OCys.

**Discussion**

In the current study, we found that OCys in PD were both functionally and morphologically abnormal. As shown in Figure 1, OCys adjacent to PDLs of a PD patient and from \textit{MVNP} mice have shorter dendritic processes compared with OCys from a normal patient and WT mice respectively. \textit{MVNP} OCys also expressed lower levels of genes associated with OCy maturation, such as sclerostin, DMP1 and FGF23, and higher levels of collagen type1 and BSP compared with \textit{Igf1-cKO}, \textit{MVNP/Ifg1-cKO}, and WT mice.
In support of this notion are our similar findings for expression of OCy maturation markers in primary osteocytic cells isolated from MVNP and WT mouse bones (Figure 3). We recently reported that pagetic OCLs and OCLs expressing MVNP produce high levels of IGF1 that are required for development of pagetic OCLs and PDLs in MVNP mice (8, 9). Our current results suggest that these changes in OCy marker gene expression may reflect effects of OCL-IGF1 on OCy differentiation. PDLs were also seen in T-Igf1 mice created to study the contribution of OCL-IGF1 to OCy (Figures 8 and 9). This seems likely, since OCys from MVNP/Igf1-cKO mice have more normal-appearing OCys. Further, IGF1 treatment of WT or MVNP OCys decreased sclerostin expression (Supplemental Figure 5). The shorter dendritic processes of OCys in the bone biopsy of a PD patient and MVNP mice could reflect a block in transition of osteoid OCys to mature OCys or decreased expression of genes involved in dendrite formation, such as or E11 or kalirin (17).

Interestingly, OCys in MVNP mice with PDLs had significantly decreased canalicular length and sclerostin expression per bone area compared with OCys in MVNP mice lacking PDLs (Figure 2). This difference may be due to the increased OCL numbers/bone area in bones with a PDL, which could result in increased local OCL-IGF1 levels compared with bones from MVNP mice without PDLs. Our finding that serum levels of IGF1 (9) and sclerostin in the 4 genotypes were similar (Figure 1D), in combination with the presence of normal appearing OCys in MVNP/Igf1-cKO mice, support the importance of high local IGF1 in PDL formation.

The basis for impaired differentiation of OCys in MVNP mice is unclear. Possibly, this may result from increased expression of Runx2 in late OBs induced by OCL-IGF1. Komori et al. reported that forced expression of Runx2 in late-stage OBs suppresses their differentiation into OCys, using a mouse model in which Runx2 was forcibly expressed in late-stage OBs driven by an osteocalcin promoter (18, 19). We previously found that IGF1 increases the expression of EphB4 and Runx2 in primary OBs from MVNP mice (8). As shown in Supplemental Figure 6A, the expression of Runx2 was only increased in MVNP OCys derived from day 30 cultures. Furthermore, when IGF1 was added to cultures of late OBs (day 15 of culture), Runx2 expression in OBs in MVNP mice was increased 6.9-fold compared with WT mice treated with vehicle (Supplemental Figure 6B). These results suggested that OCL-derived IGF1 induces the expression of Runx2 in OBs and impedes their differentiation into OCys.

In support of this notion, primary OCys isolated from MVNP and WT mouse bones showed similar changes in OCy gene expression as OCy-like cells present in 30-day outgrowth cells from bones of MVNP and WT mice. Sost mRNA levels in primary OCys from MVNP mice were 30% lower than those in primary OCys from WT mice. Sclerostin expression by immunohistochemical analysis of primary OCys showed a similar pattern of results (Figure 3).
OCys present in the canalicular lacunae of MVNP mice showed increased RANKL expression and secretion compared with MVNP/Igf1-cKO, Igf1-cKO, and WT mice (Figure 4A). The numbers and percentages of RANKL-expressing OCys were significantly increased in MVNP mice compared with the other genotypes (Figure 4B), although serum RANKL was similar in all genotypes. Further, RANKL in CM of OCys from MVNP mice was significantly higher than in CM of the other genotypes (Figure 4, C and D). These results suggest that RANKL production by OCys is increased in PD patients who have prolonged exposure to high local OCL-IGF1. These high local levels of RANKL may induce formation of large numbers of PD OCLs that secrete high levels of IGF1. Since PD OCL precursors...
are hyperresponsive to RANKL (20, 21), IGF1 may then induce OCy RANKL production that further increases PD OCL formation, eventually resulting in a PDL. Consistent with this notion, coculture of MVNP OCL precursors and MVNP OCys showed increased pagetic OCL formation, and the CM of these cocultures contained higher RANKL levels compared with cocultures of WT OCL precursors with OCys from WT and MVNP mice (Figure 5). Importantly, when MVNP OCys transduced with Igflr siRNA (MVNP-Igf1r siRNA-OCy) or control siRNA were cocultured with MVNP OCL precursors, OCL formation and RANKL levels in CM of MVNP OCL precursors with MVNP-Igf1r siRNA-OCys were significantly lower (65%) versus MVNP-control siRNA-OCys cocultures. Further, addition of anti-IGF1 or anti-IGF1R antibodies to these cocultures similarly suppressed expression of a pagetic phenotype in MVNP OCLs. In addition, anti-IGF1R treatment of MVNP OCL precursors cocultured with MVNP OCys on bone slices decreased the bone resorption rate by 80% compared with control-IgG-treated cocultures. In addition, the observation of p-Akt in OCys of bone sections from MVNP and T-Igf1 mice suggests that IGF1 activates signaling in OCys (Figure 9A). These results demonstrate that PD OCL-IGF1 induces RANKL and decreases sclerostin expression in OCys.

Pagetic OCLs in MVNP mice express elevated IGF1, and OCL-cKO of Igf1 blocks local PDL formation in this model, while further increases in IGF1 secretion by OCLs may increase PDLs. We showed previously that IL-6, while insufficient to initiate pagetic lesions, could enhance the effects of IGF1 (8). To evaluate whether elevated levels of OCL-IGF1 alone are sufficient to induce PDL and pagetic OCLs, we generated a T-Igf1 mouse that overexpresses IGF1 in OCLs. As shown in Figure 8, PDLs were induced by overexpression of IGF1 in OCLs. At 16 months of age, PDLs were found in 54% of T-Igf1 mice, allowing us to distinguish the contribution of IGF1 effects on OCys in PD, and the increased OCL-IGF1 secretion by PDLs in the absence of MVNP expression was sufficient to induce PD.

Finally, 25% of OCys at sites of PDLs showed senescence, and RANKL secretion was observed in these OCys, suggesting a relationship between senescence and PDLs (Figure 9D). Most recently, Farr et al. reported that deletion of p16 from OCys reduced RANKL from OCys (16). Insulin/IGF1 signaling induces intracellular oxidative burden and associated oxidative damage (22). IGF1 induces specific p53 acetylation via inhibition of SIRT1, leading to premature senescence (23).

Taken together, our results with T-Igf1 and MVNP/Igf1-cKO mice support a model in which OCL-IGF1 induces PD OCL formation and PDLs. A small collection of PD OCLs secrete high local levels of IGF1 that induce local OCy RANKL production, suppress OCy sclerostin expression, and enhance formation of PD OCLs from OCL precursors that are hyperresponsive to RANKL. This increases local bone destruction. OCy-derived RANKL could in turn recruit additional PD OCL precursors to this specific site in bone, analogous to OCL recruitment by apoptotic OCys. This could result in multiple cycles of PD OCL formation that increases local bone destruction and can induce local rapid bone formation via the expression of the coupling factors EphB2 on OCLs and EphB4 on OBs (8). IGF1 further stimulates local bone formation and development of PDLs (8, 9) in a bone site with low sclerostin levels. Thus, our results suggest that OCys play a key role in PDL formation in PD.

Methods

Chemicals. Rabbit IgG (catalog AB-105-C), anti-IGF1 (catalog AF791), and anti-IGF1R (catalog MAB391-100) were purchased from R&D Systems. αMEM was from Thermo Fisher Scientific and FBS from Sigma-Aldrich. An anti-p-Akt antibody (catalog 9271) was purchased from Cell Signaling Technology. An anti-p16INK4A antibody (catalog 03119) was purchased from GeneTex.

Table 1. The number of mice and PDLs in T-Igf1 or WT mice

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>T-Igf1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of mice</td>
<td>Male 5 6 6 6</td>
<td>Female 0 0 1 5</td>
</tr>
<tr>
<td>PDLs</td>
<td>0 0 1 5</td>
<td>0 0 1 5</td>
</tr>
</tbody>
</table>

PD lesions (PDLs) were screened by μCT and IHC as described in Methods. Markedly abnormal structure was seen in 6 of the 12 T-Igf1 mice (50%) at 16 months of age.
Animal studies. Animals were housed at Virginia Commonwealth University in individually ventilated cages in a barrier vivarium, which excludes all known mouse viruses and parasites and most bacteria (including *Helicobacter*). The mice were fed standard mouse chow (irradiated Teklad LM-485 diet) and autoclaved water. Mice of both sexes and multiple ages were euthanized under isoflurane anesthesia, followed by cervical dislocation for collection of bone tissues, which were shipped overnight to Indiana University School of Medicine in DMEM plus 10% FBS with penicillin/streptomycin at 20°C.
Isolation of primary OCys from mouse long bones. Primary osteocytes were isolated from femurs and tibiae of WT and MVNP mice, according to a method previously described by Miyagawa et al., with modifications (28). Briefly, mouse tibiae and femurs were minced into 0.5-mm pieces and digested with 1.25 mg/mL collagenase (Wako) in Ca²⁺-, Mg²⁺-free Hanks' balanced salt solution (HBSS) at 37°C. Cells released
after the first and second (15 minutes each) and third to fifth (20 minutes each) digestion were collected through a 100-μm nylon cell strainer as fractions 1 to 5, respectively. Residual bone pieces were treated with 4 mM EGTA in Ca2+-free, Mg2+-free HBSS for 15 minutes and then with 1.25 mg/mL collagenase for 20 minutes at 37°C to collect cells for OCy-rich fractions (fractions 6 to 9).

Isolation of OBs and OCy-like cells. After flushing the BM from tibiae and femurs of WT, Igf1-cKO, MVNP, and MVNP/Igf1-cKO mice, the bones were cultured in αMEM plus 10% FCS for 15 days. The original bone was removed, and the outgrowth cells from the bone were treated with 0.25% trypsin and 0.05% EDTA for 10 minutes at 37°C. These cells were used as primary OBs without further passage (8, 9). Cells were either stained for alkaline phosphatase or with alizarin red, or cell lysates were collected and analyzed for protein expression. Similarly, cells separated by trypsin from the outgrowth cells of bones that had been cultured for 30 days were used as OCy-like cells without further passage. As shown Supplemental Figure 1A, cells derived from day 15 outgrowth cells of bones expressed OB markers. Cells from day 30 culture expressed the OCy markers sclerostin, DMP1, and ORP150 by Western blotting and were used to determine RANKL derived from day 15 outgrowth cells of bones expressed OB markers. Cells from day 30 culture expressed the

OCy formation from purified OCL precursors. Nonadherent BM cells were harvested and enriched for CD11b+ mononuclear cells using CD11b microbeads (MACS, 120-000-300) and a Miltenyi Biotec MACS magnetic cell-sorting system. These cells were cultured with 10 ng/mL M-CSF (R&D Systems) in αMEM containing 10% FCS for 3 days. This stage of purified OCL precursor expresses RANK receptor and TRAP (8) and forms OCLs in the presence of 50 ng/mL RANKL for 2–4 days. The cells were stained for TRAP (Sigma-Aldrich), and TRAP+ multinucleated cells (≥3 nuclei/cell) were scored as OCLs.

Coculture of purified OCL precursors and OCy-like cells. OCL precursors (5 × 10^4/well) and OCy-like cells (5 × 10^4/well) isolated by the methods described above were cocultured in αMEM with 10% FCS for 72 hours in 96-well plates.

Transfection of Igf1r siRNA into OCy-like cells. OCy-like cells (5 × 10^4) were plated in 96-well plates 12 hours before transfection with 100 nM siRNAs. Control siRNA (Cell Signaling, 6568) or mouse-specific Igf1r siRNA (Cell Signaling, 12482) were transfected into OCy-like cells as described previously (29).

Isolation of mature OCLs from BM cultures. BM cells flushed from long bones of WT or MVNP mice were cultured (2.5 × 10^7 cells/10-cm dish) with 10 ng/mL M-CSF for 3 days, followed by 50 ng/mL RANKL for 4 days as described previously (8). At the end of culture, trypsin-EDTA (Corning) was added for 3 minutes to remove non-osteoclastic cells. OCLs were released from the plates by gently scraping with a rubber policeman.

Coculture of OCLs and OCy-like cells for bone resorption. OCLs (2 × 10^5/well) and OCy-like cells (5 × 10^4/well) were cocultured on bovine bone slices (Immunodiagnostic Systems, DT-1BON1000-96) in 96-well plates with αMEM plus 10% FCS with and without anti-IGF1R (0.5 μg/mL) for 72 hours. The cells were then removed, the bone slices stained with acid hematoxylin, and the areas of bone resorbed determined as previously described (30).

RNA extraction and real-time PCR analysis. Total RNA was extracted using TRIzol (Invitrogen), treated with DNase (Qiagen), and reverse transcribed with random hexamers (Promega) and SuperScript II (Invitrogen). cDNA was analyze using TaqMan with Real Time PCR (Applied Biosystems). To generate a standard curve for real-time PCR, amplicons of interest were first cloned into a pT7-blue vector (Novagen), and serial 10-fold dilutions of the plasmid included in the assay. The copy number of the target cDNA in each sample was estimated by referring to the standard curve, which was standardized to that of Gapdh in each sample. Specific primers were Sost forward, 5′-TCCTGAGAAACACAGACAC-3′ and reverse, 5′-GCCAGCTGTACTCGGACACATC-3′; Igf1 forward, 5′-ACCGAGGGCCCTTTATCT-3′ and reverse, 5′-TGCCCTACCTTTCTCTCC-3′; Tnfsf11 forward, 5′-AGCCATTGGCACAACCTCAC-3′ and reverse, 5′-CGTGGTTACCAAGAGGACAGAGG-3′; Gapdh forward, 5′-GTGTTTCTACACCCCAATGTG-3′ and reverse, 5′-ATAGGGGCCCTCTGCTCAG-3′.

Sclerostin, RANKL, and IGF1 ELISAs. Collected mouse sera were stored at –80°C until tested. Sclerostin and IGF1 were measured using ELISA kits for murine Sost (Abcam, ab213889) and murine IGF1 (Abcam, ab100695), and RANKL was measured using an ELISA kit for murine/rat RANKL (R&D Systems, MTR00), according to the manufacturers’ instructions.

μCT and histomorphometry. Femora, tibiae, and vertebrae from WT, TRAP-Igf1, and MVNP mice at 16 months of age were fixed in 10% buffered formalin at 4°C. Bone microstructure analyses were performed using a μCT scanning system (Viva CT 40, Scanco Medical) with an isotropic voxel size of 10.5 μm and the scanner settings of 55 kVp, 25 μA, and 350 ms integration time. Structural parameters were analyzed
in reconstructed 3-dimensional images using evaluation software (μCT v1.6, Scanco Medical) according to the recommended guideline (31). The regions of interest were defined using previously described methods (32, 33). The cancellous bone and marrow compartments of the L5 vertebral body were examined between the cranial and caudal growth plates. The cortical bone parameters were analyzed in 100 slices at the tibial midshaft, starting 5.5 mm from the proximal metaphysis. The μCT data were then exported as a sequence of 8-bit DICOM grayscale images, and simultaneous multiplanar reconstructed (MPR) images were viewed using ImageJ software.

The lumbar vertebrae were decalcified in 10% EDTA at 4°C and embedded in paraffin. OCLs containing active TRAP were stained red, as described by Liu et al. (34). OCL perimeter (OCL surface/bone surface, Oc.S/BS) was defined as the length of bone surface covered with TRAP+ multinuclear cells. OB perimeter (Ob.S/BS) was also measured in the same field.

**Statistics.** Significance was evaluated using 1-way ANOVA with Tukey’s test. Differences with \( P \) less than 0.05 were considered significant.

**Blinding.** To avoid bias, all data were collected in a blinded fashion, with the observer unaware of the experimental group. Key studies were performed by more than 1 individual to confirm observational consistency.

**Study approvals.** All animal studies were performed as described in approved IACUC protocols from Virginia Commonwealth University and Indiana University and an ACURO protocol from the Department of Defense, in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). Human patient samples used deidentified archival material not collected for this study and were IRB exempt.

**Author contributions**

GDR, JMC, and NK designed the study, interpreted the data, and wrote the manuscript. KM, HT, PLM, JDC, and NK performed the experiments. MAS and JJW designed and generated the transgenic mice.

**Acknowledgments**

This work was supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): NIH R01-AR057308 and R01-AR090116-01 (both to GDR). Services in support of this research project were provided by the Virginia Commonwealth University Massey Cancer Center Transgenic/Knockout Mouse Core, supported in part with funding from NIH-NCI Cancer Center Support grant P30 CA016059.

Address correspondence to: G. David Roodman, Department of Medicine, Hematology/Oncology, School of Medicine, Indiana University, 980 West Walnut Street, Suite C312, Indianapolis, Indiana 46202, USA. Phone: 317.278.6255; Email: groodman@iu.edu.

---


